Traditional Chinese medicine compound, Bu Sheng Hui Yang Fang, promotes the proliferation of lymphocytes in the immunosuppressed mice potentially by upregulating IL-4 signaling.

Dec 21, 2020

Contributor: Yajie Wang,Jiabin Tan,Peng Hu,Qiang Pei,Yan Wen,Wenqing Ma,Keqian Shi,Zengzheng Li,Huiyuan Li,Fengyu Cheng,Xuezhong Gu,Xiangmei Yao,Yan Man,Renbin Zhao,Shuai Feng,Xiao Ding,Tonghua Yang

Traditional Chinese medicine compound, Bu Sheng Hui Yang Fang, promotes the proliferation of lymphocytes in the immunosuppressed mice potentially by upregulating IL-4 signaling.

The immune system plays a pivotal role in defending against infection and cancer immunosurveillance during the onset and procession of malignant disease. Cancer patients are frequently immunocompromised and subject to refractory infection and relapse of leukemia, due to the cytotoxic agents and immunosuppressive glucocorticoids in the chemotherapy regimens. Bu Shen Hui Yang Fang (BSHY), a traditional Chinese compound, was widely used in China to enhance the immune system of leukemia patients combined with chemotherapy and effectively lowered their risk of infection, with specific mechanism unknown yet. Thus, we investigated the effects of BSHY on the immune system using immunosuppressive mouse models. By analyzing the immune system of immunosuppressed BALB/C mice induced by hydrocortisone, we found an increase of CD4 and CD8 lymphocytes in the spleens of mice after BSHY treatment. Furthermore, we found the enhanced immune system in BSHY treated group was due to increased proliferation and decreased apoptosis of lymphocytes. Cytokine array analysis revealed that interleukin 4 (IL-4) was reduced in the plasma of immunosuppressed mice but returned to a normal level after BSHY treatment. Moreover, we found IL-4 was an adverse prognostic factor in acute myeloid leukemia patients and part of them could be elevated by BSHY. Mechanistically, we found BSHY enhances the proliferation of lymphocytes in a Stat6-dependent manner. In summary, our current study demonstrates that BSHY enhances the proliferation of lymphocytes in the immunosuppressed mice via upregulating IL-4 signaling.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Author

admin

View all posts

About The Expert

Yajie Wang

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Jiabin Tan

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Peng Hu

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Qiang Pei

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Yan Wen

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Wenqing Ma

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Keqian Shi

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Zengzheng Li

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Huiyuan Li

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Fengyu Cheng

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Xuezhong Gu

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Xiangmei Yao

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Yan Man

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Renbin Zhao

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Shuai Feng

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China.

Xiao Ding

State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, China. Electronic address: dingxiao@mail.kib.ac.cn.

Tonghua Yang

Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China; Kunming University of Science and Technology, Kunming, China. Electronic address: ynanblood@aliyun.com.

References

PubMed